You are currently browsing the archives for the Bio-Rad Promotions category.

Archive for the ‘Bio-Rad Promotions’ Category

Get a Free Sample of TGX Stain-Free™ FastCast™ Acrylamide Solutions

 :: Posted by American Biotechnologist on 06-26-2014

If you hand cast your own gels, TGX Stain-Free FastCast acrylamide solutions will give you a fresh perspective. Request a free sample and experience how these innovative solutions increase the efficiency of your 1-D electrophoresis or western blotting experiments. It truly is happiness in a bottle.

Faster Performance

  • Achieve electrophoretic run times as short as 20 minutes
  • Enjoy protein transfers in as little as 3 minutes using the TransBlot® Turbo™ transfer system

Stain-Free Visualization*

  • Monitor the success of electrophoresis and transfer steps without additional staining
  • Visualize proteins in your gel or blot in less than 5 minutes with Bio-Rad’s stain-free enabled imaging systems

Longer Shelf Life

  • Gels last up to 1 month at 4°C after casting
  • Shelf life of acrylamide solutions is 1 year at room temperature
CLICK TO EXPAND

CLICK TO EXPAND

* The Quick Start Guide to Stain-Free Imaging provides step-by-step instructions on how to obtain stain-free images from TGX Stain-Free gels. If you do not have access to a Bio-Rad stain-free enabled imager, your gels can be stained using traditional staining methods.

Bio-Rad Laboratories Awarded Best New Life Sciences Product of 2013

 :: Posted by American Biotechnologist on 05-01-2014

SelectScience was delighted to announce the QX200™ Droplet Digital™ PCR System, by Bio-Rad, as the winner of the Scientists’ Choice Award for Best New Life Sciences Product of 2013. The award was presented to Bio-Rad at the American Association for Cancer Research (AACR) Annual Meeting 2014.

Click on the photo below to navigate to the SelectScience website and view the video.

select science ddpcr award

Designing the Perfect Quantitative Western Blot

 :: Posted by American Biotechnologist on 04-02-2014

A methods article published yesterday provides a rigorous and concise workflow with specific instructions on how to produce and analyze quantitative data using western blot experiments. The paper, coauthored by Bio-Rad scientists and published in BioMed Research International, also highlights recently introduced technologies that improve reproducibility. The result is a powerful, step-by-step guide to obtaining quantitative and reproducible densitometric data from western blots regardless of the specific experiment.

Although western blotting is a well-established laboratory technique, it has recently come under fire as a quantitative method because extreme care must be taken when generating and interpreting the resulting data.

The technique is challenging and requires following a rigorous methodology to achieve reproducible and quantitative data. According to a recent survey of more than 750 labs, 41% of researchers say their western blots fail a quarter of the time.

Dr. Aldrin Gomes, an assistant professor at University of California, Davis, agrees that flawed western blots are not unusual. To compare expression of a protein of interest from sample to sample, protein abundance is commonly normalized to a housekeeping gene. “When I see a large, dense band for the protein of interest or the housekeeping protein, I cringe,” says Gomes. That dense band usually means the protein of interest or housekeeping protein was no longer within the assay’s linear dynamic range. No accurate quantitative data can be extracted from such blots.

Sean Taylor discusses the BioMed Research International paper he coauthored.

Another common reason for failure of quantitative western blots is flawed or incomplete protocols, according to Sean Taylor, the paper’s lead author and a Bio-Rad field application scientist (watch a video of him discussing the paper on the left). To address this, Taylor’s review pays special attention to experimental design and sample preparation and discusses proper definition of the linear dynamic range of protein loading, all key factors for generating meaningful quantitative western blot data.

Taylor also introduces more advanced concepts to improve reproducibility, simplify workflow, and reduce the time and cost of western blotting. One such technique is stain-free total protein normalization, which over the past year has proven superior to using housekeeping proteins or total protein staining to correct for loading errors.

With this article, Taylor hopes researchers now have a simple guide to ensure quantitative and reproducible western blot data for all research fields that rely on this technique.

To read the open access research article, visit http://bit.ly/1kCAOcr.

For additional resources please consult Bio-Rad’s guide to Troubleshooting Western Blots.

Life Since the Double Helix

 :: Posted by American Biotechnologist on 02-18-2014

The discovery of the double-helix structure of DNA 60 years ago led to a revolution in biological science, opening the floodgates for myriad subsequent discoveries and spawning new fields of research. Bio-Rad has been there from the beginning, helping scientists, educators, and clinicians advance basic research and improve healthcare. As we celebrate Bio-Rad’s diamond anniversary, we reflect on the major events in the evolution of life science research, from biochemistry to molecular biology and beyond, and the emergence of modern biotechnology.

Read more…

Droplet Digital PCR enables measurement of potential cancer survival biomarker

 :: Posted by American Biotechnologist on 01-09-2014

Researchers at Fred Hutchinson Cancer Research Center have used Droplet Digital PCR (ddPCR™) to demonstrate for the first time the quantification of a special class of tumor-attacking immune cell known to improve cancer survival, a subpopulation of T-cells called tumor-infiltrating T-lymphocytes or TILs. The study, led by Dr. Jason Bielas, Associate Member of the Public Health Sciences Division at Fred Hutch, paves the way for further study of the role of TIL quantification in immunotherapy and as a cancer survival predictor.

“Now that we have the sensitivity and ability to reproducibly count TILs in tumors, we may be able to stratify and more effectively treat patients based on tumor TIL count, especially with immunotherapeutics coming to market,” said Dr. Bielas, one of the lead authors of a paper reporting the TIL quantification results in Science Translational Medicine.

Quantifying TILs Using ddPCR

TILs directly attack tumor cells in a variety of cancer types. While the presence and quantity of TILs strongly correlate with increased patient survival, current tests are semiquantitative at best. As a result, TILs cannot be used for clinical decision making.

According to Dr. Bielas, TILs have a “genomic signature that can be digitally exploited.” This signature, which exhibits a vast amount of diversity, determines the genetic identity, or clonality, of the T-cell receptors (TCR) expressed on the surface of each TIL. With the advent of digital PCR – and the generation of tens of thousands of data points produced by Droplet Digital PCR – it is now possible to quantify these signatures, enabling the determination of the number of TILs.

“There’s no way you could do this with any method other than digital PCR because of the numerous primer pairs and probes that we have (45 forward primers, 13 reverse primers, and 30 probes),” said Dr. Bielas. “Digital PCR partitions all the reactions so you can amplify these targets independently of PCR efficiency without any competing side reactions.”

Fred Hutch researchers developed the Droplet Digital PCR-based “QuanTILfy” assay using Bio-Rad Laboratories’ QX100 ddPCR system. They then used QuanTILfy to count TILs, determine their frequency, and develop a grouping system to classify “clonality,” which might be a marker of druggable targets.

Study Results

Fred Hutch researchers performed the QuanTILfy assay on primary tumors from 30 ovarian carcinoma patients with known survival outcomes, ranging from 1 to 122 months. TIL frequency was approximately threefold higher in patients with a survival rate of more than five years compared with patients with survival rates of less than two years. These results show that higher TIL levels correlate positively with patient survival, consistent with the hypothesis that TILs play an active role in suppressing tumor formation.

The researchers also demonstrated that QuanTILfy can be used to accurately and reproducibly characterize T-cell clonality in patients with T-cell acute lymphoblastic leukemia. In each case, they saw a single QuanTILfy assay subgroup, indicative of clonal T-cell expansion. This finding was confirmed by deep sequencing.

The QuanTILfy assay proved to be both sensitive and accurate. In a mixture of human T-cells purified from blood and normal human lung fibroblasts, the assay demonstrated the ability to detect a single TCR rearrangement among 10,000 tumor cells. Importantly, it also demonstrated the ability of ddPCR technology to quantify a large number of markers simultaneously in a single reaction through multiplexing.